Fig. 5

EGFR-TKI and PTK2 co-inhibition improved therapeutic efficacy in a xenograft model. a Viability of OUS-11 cells treated with 1 μM defactinib and osimertinib at the indicated concentrations for 96 h. Data are means (SD), n = 3. *, P < 0.05; ***, P < 0.001, by Student’s t-test. b Immunoblots of PARP and cleaved PARP in PC-9/PEM clone1 and OUS-11 cells with or without 1 μM defactinib (Def) and 0.1 μM osimertinib (Osi) following long and short exposing time. c and e Tumor volume of xenografts of PC-9 (c) and PC-9/PEM clone1 (e) were measured over time of the treatment after inoculation and the results are shown. Data are means (SD), n = 6. d and f Changes in tumor volumes of xenografts of PC-9 (d) and PC-9/PEM clone1 (f). Data are means (SD), n = 6. g and h Changes in tumor volumes of xenografts at day 30 for PC-9 (g) and PC-9/PEM clone1 (h). Data are means (SD), n = 6. *, P < 0.05; **, P < 0.01, NS, not significant. Groups were compared by one-way ANOVA and Tukey’s HSD multiple comparisons test